HHS, DOD award $481M for point-of-care COVID-19 test, announce vaccine manufacturer partnership
The Department of Health and Human Services and the Department of Defense yesterday awarded $481 million to Cue Health Inc. to expand production of a point-of-care COVID-19 molecular test with capabilities to produce results in 20 minutes.
Cue said the highly sensitive test uses a nasal swab sample to detect RNA of SARS-CoV-2, the virus that causes COVID-19. HHS said the partnership allows Cue to increase production to 100,000 test kits per day by March 2021.
Also yesterday, HHS and DOD announced a separate, $31 million agreement with Cytiva to expand the company’s capacity to produce items essential to the production of COVID-19 vaccines such as liquid and dry powder cell culture media, cell culture buffers, mixer bags, and bioreactors.
Related News Articles
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…